Your AI-Trained Oncology Knowledge Connection!
Investigators indicated that comprehensive geriatric assessment could be used to determine whether older, frail patients with hematologic cancers can undergo intensive treatment with chemotherapy and whether curative treatment is viable.
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
Chemoradiotherapy plus cisplatin administered weekly was found to be non-inferior to cisplatin once every 3 weeks for patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
A de-escalated regimen of trastuzumab and pertuzumab without added paclitaxel may be an option for certain patients with HER2-positive, hormone receptor–negative early-stage breast cancer.
A biologics license application for pegfilgrastim-pbbk was accepted by the FDA for use in patients experiencing neutropenia while receiving chemotherapy.
Semi-structured qualitative interviews revealed that patients undergoing allogeneic hematopoietic stem cell transplant could benefit from peer support prior to and during transplantation.
Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.
Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.
Results from the phase 2 ELARA trial supported an accelerated approval from the FDA for tisagenlecleucel for patients with relapsed/refractory follicular lymphoma.
The FDA has granted approval to nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.
Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.
Adverse effects were found to be similar between patients with metastatic hormone-sensitive prostate cancer who were treated with darolutamide plus androgen deprivation therapy and docetaxel vs androgen deprivation therapy and docetaxel alone.
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.
Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.
Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.
European patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence can now receive treatment with neoadjuvant pembrolizumab and chemotherapy, as well as pembrolizumab monotherapy post surgery following its approval by the European Commission.
Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.
Findings from the phase 3 DeFi study indicated that treatment with nirogacestat met the trial’s end points in patients with progressing desmoid tumors.
Alina Markova, MD, speaks about future research efforts for topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease, and multidisciplinary implications of current research.
Interim results from the phase 2 PADRES trial demonstrated that partial nephrectomy may be possible for a subgroup of patients with clear cell renal cell carcinoma with complex masses who received neoadjuvant axitinib.
Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.
Results from the phase 2 BIONIKK trial highlighted the feasibility and positive impact of selecting patients with metastatic clear cell renal cell carcinoma for treatment with nivolumab plus or minus ipilimumab and a VEGFR-tyrosine kinase inhibitor based on molecular phenotype.
Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.
Uday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.
Patients who are black had a longer overall survival after investment was made for public welfare programs concerning those with cancer.
The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.
A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.
The phase 3 ALTER 0303 trial demonstrated that although patients with non–small cell lung cancer and liver metastases have a worse prognosis than those without, treatment with anlotinib may result in better progression-free survival vs a placebo.
Early discontinuation of a hypomethylating agent was associated with an increase in economic burden for those with refractory anemia with excess blasts, a diagnosis that overlaps with high-risk myelodysplastic syndrome.
Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.
